Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Melanoma|Head and Neck Squamous Cell Carcinoma
BIOLOGICAL: TILT-123|DRUG: Avelumab
Number of Participants with any (serious and non-serious) Adverse Events., Safety I, 85 days|Number of Participants with abnormal laboratory values., Safety II, 85 days|Number of Participants with vital sign abnormalities., Safety III, 85 days|Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs), Safety IV, 85 days
This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 TILT-123 in combination with avelumab in patients with advanced solid tumors (SCCHN and melanoma) refractory to or progressing after anti-PD(L)1. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial is conducted in Helsinki (Finland).